Astma: Patogeneza i leczenie

Allergic asthma is triggered by allergens like dust mites, pollen, and pet dander, involving an IgE-mediated immune response. Non-allergic asthma results from direct airway hyper-responsiveness to non-immune triggers such as cold air, exercise, air pollutants, respiratory infections, or strong emotions. Both types cause similar symptoms including wheezing, shortness of breath, and chest tightness, but through different pathogenic mechanisms.

During sensitization, IgE antibodies bind to mast cells in the airway mucosa, priming them. Upon re-exposure to allergens, primed mast cells release inflammatory mediators like histamine, leukotrienes, and prostaglandins. These substances trigger bronchial muscle contraction, mucus secretion, and vascular leakage, initiating the immediate asthma response. Understanding mast cell activation is central to antiasthma drugs mast cell stabilizers and anti-IgE drugs.

Hours after the initial mast cell response, eosinophils and lymphocytes infiltrate the airways and release inflammatory proteins called interleukins. This late-phase response sustains bronchoconstriction, inflammation, and mucus production, contributing to the chronic nature of asthma. The prolonged inflammatory cascade explains why asthma symptoms can persist even after allergen exposure ends.

Corticosteroids such as fluticasone and budesonide are powerful anti-inflammatory agents that reduce swelling and mucus production in the airways. By suppressing the inflammatory response, inhaled corticosteroids and glucocorticoids help prevent bronchoconstriction and restore normal airway function. With appropriate use of these medications, asthmatic individuals can manage symptoms and lead active lives.

Bronchodilators such as albuterol and salmeterol act as sympathomimetics that relax bronchial smooth muscles and open the airways. These medications provide rapid relief from bronchoconstriction and restore airflow during asthma attacks. Bronchodilators are essential components of asthma management, often used alongside anti-inflammatory agents for optimal symptom control.

Primed mast cells release histamine, leukotrienes, and prostaglandins upon allergen re-exposure. In non-allergic asthma, direct airway activation also releases histamine and leukotrienes. These mediators cause bronchial muscle contraction, mucus secretion, and increased blood vessel permeability, collectively producing the characteristic asthma symptoms of wheezing and airway obstruction.

Asthma pathogenesis involves an immune response specifically in genetically predisposed individuals. During sensitization, these individuals produce IgE antibodies in response to allergen exposure, priming mast cells for future encounters. Genetic factors determine whether the immune system mounts this exaggerated IgE response, making some people susceptible to asthma while others exposed to the same allergens remain unaffected.